167 related articles for article (PubMed ID: 18765669)
1. Ectodomain lysines and suramin block of P2X1 receptors.
Sim JA; Broomhead HE; North RA
J Biol Chem; 2008 Oct; 283(44):29841-6. PubMed ID: 18765669
[TBL] [Abstract][Full Text] [Related]
2. Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist.
Rettinger J; Braun K; Hochmann H; Kassack MU; Ullmann H; Nickel P; Schmalzing G; Lambrecht G
Neuropharmacology; 2005 Mar; 48(3):461-8. PubMed ID: 15721178
[TBL] [Abstract][Full Text] [Related]
3. The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups.
Hausmann R; Rettinger J; Gerevich Z; Meis S; Kassack MU; Illes P; Lambrecht G; Schmalzing G
Mol Pharmacol; 2006 Jun; 69(6):2058-67. PubMed ID: 16551782
[TBL] [Abstract][Full Text] [Related]
4. NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors.
Braun K; Rettinger J; Ganso M; Kassack M; Hildebrandt C; Ullmann H; Nickel P; Schmalzing G; Lambrecht G
Naunyn Schmiedebergs Arch Pharmacol; 2001 Sep; 364(3):285-90. PubMed ID: 11521173
[TBL] [Abstract][Full Text] [Related]
5. Use of chimeras, point mutants, and molecular modeling to map the antagonist-binding site of 4,4',4″,4‴-(carbonylbis-(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakisbenzene-1,3-disulfonic acid (NF449) at P2X1 receptors for ATP.
Farmer LK; Schmid R; Evans RJ
J Biol Chem; 2015 Jan; 290(3):1559-69. PubMed ID: 25425641
[TBL] [Abstract][Full Text] [Related]
6. NF449, a novel picomolar potency antagonist at human P2X1 receptors.
Hülsmann M; Nickel P; Kassack M; Schmalzing G; Lambrecht G; Markwardt F
Eur J Pharmacol; 2003 May; 470(1-2):1-7. PubMed ID: 12787824
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt].
Hechler B; Magnenat S; Zighetti ML; Kassack MU; Ullmann H; Cazenave JP; Evans R; Cattaneo M; Gachet C
J Pharmacol Exp Ther; 2005 Jul; 314(1):232-43. PubMed ID: 15792995
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino acids in the cysteine-rich loop.
El-Ajouz S; Ray D; Allsopp RC; Evans RJ
Br J Pharmacol; 2012 Jan; 165(2):390-400. PubMed ID: 21671897
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.
Kassack MU; Braun K; Ganso M; Ullmann H; Nickel P; Böing B; Müller G; Lambrecht G
Eur J Med Chem; 2004 Apr; 39(4):345-57. PubMed ID: 15072843
[TBL] [Abstract][Full Text] [Related]
10. Identification of atropine- and P2X1 receptor antagonist-resistant, neurogenic contractions of the urinary bladder.
Kennedy C; Tasker PN; Gallacher G; Westfall TD
J Neurosci; 2007 Jan; 27(4):845-51. PubMed ID: 17251425
[TBL] [Abstract][Full Text] [Related]
11. Dissecting individual current components of co-expressed human P2X1 and P2X7 receptors.
Seyffert C; Schmalzing G; Markwardt F
Curr Top Med Chem; 2004; 4(16):1719-30. PubMed ID: 15579104
[TBL] [Abstract][Full Text] [Related]
12. The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.
Horner S; Menke K; Hildebrandt C; Kassack MU; Nickel P; Ullmann H; Mahaut-Smith MP; Lambrecht G
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):1-13. PubMed ID: 16158305
[TBL] [Abstract][Full Text] [Related]
13. Divergent effects of the purinoceptor antagonists suramin and pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) (PPNDS) on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.
Suzuki E; Kessler M; Montgomery K; Arai AC
Mol Pharmacol; 2004 Dec; 66(6):1738-47. PubMed ID: 15448189
[TBL] [Abstract][Full Text] [Related]
14. The role of positively charged amino acids in ATP recognition by human P2X(1) receptors.
Ennion S; Hagan S; Evans RJ
J Biol Chem; 2000 Sep; 275(38):29361-7. PubMed ID: 10827197
[TBL] [Abstract][Full Text] [Related]
15. Lack of run-down of smooth muscle P2X receptor currents recorded with the amphotericin permeabilized patch technique, physiological and pharmacological characterization of the properties of mesenteric artery P2X receptor ion channels.
Lewis CJ; Evans RJ
Br J Pharmacol; 2000 Dec; 131(8):1659-66. PubMed ID: 11139444
[TBL] [Abstract][Full Text] [Related]
16. Cloning, tissue distribution and functional characterization of the chicken P2X1 receptor.
Soto F; Krause U; Borchardt K; Ruppelt A
FEBS Lett; 2003 Jan; 533(1-3):54-8. PubMed ID: 12505158
[TBL] [Abstract][Full Text] [Related]
17. Characterization of cultured dorsal root ganglion neuron P2X receptors.
Grubb BD; Evans RJ
Eur J Neurosci; 1999 Jan; 11(1):149-54. PubMed ID: 9987019
[TBL] [Abstract][Full Text] [Related]
18. Characterization of functional P2X(1) receptors in mouse megakaryocytes.
Ikeda M
Thromb Res; 2007; 119(3):343-53. PubMed ID: 16626790
[TBL] [Abstract][Full Text] [Related]
19. Purinoreceptor-mediated current in myocytes from renal resistance arteries.
Harhun MI; Povstyan OV; Gordienko DV
Br J Pharmacol; 2010 Jun; 160(4):987-97. PubMed ID: 20590593
[TBL] [Abstract][Full Text] [Related]
20. The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor.
Rettinger J; Schmalzing G; Damer S; Müller G; Nickel P; Lambrecht G
Neuropharmacology; 2000 Aug; 39(11):2044-53. PubMed ID: 10963748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]